Enanta Pharmaceuticals, Inc. (ENTA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Enanta Pharmaceuticals, Inc. (ENTA) closed at USD 11.18 on 2026-10-14, a change of +6.8 % over the past year, with a market capitalization of USD 334.07M.

Enanta Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Enanta Pharmaceuticals, Inc. key figures

Previous close

USD 11.18 (2026-10-14)

1-year change

+6.8 %

Market cap

USD 334.07M

Enterprise value

USD 326.6M

P/E ratio (trailing)

-4.76

P/E ratio (forward)

-4.83

EPS (trailing)

-2.41

EPS (forward)

-2.37

PEG ratio

n/a

Price to book

3.30

Revenue growth

-21.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.63

Employees

120

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Enanta Pharmaceuticals, Inc. and compare it with other stocks.